within Pharmacolibrary.Drugs.ATC.L;

model L04AJ06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 0.00015,
    adminDuration  = 600,
    adminMass      = 7.000000000000001e-05,
    adminCount     = 1,
    Vd             = 0.00020999999999999998,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Zilucoplan is a synthetic macrocyclic peptide complement C5 inhibitor used for the treatment of generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive. It works by preventing complement-mediated damage at the neuromuscular junction. Zilucoplan is approved for clinical use as of 2023.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult patients with generalized myasthenia gravis after subcutaneous administration.</p><h4>References</h4><ol><li><p>Versino, F, &amp; Fattizzo, B (2024). Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy. <i>International journal of laboratory hematology</i> 46 Suppl 1 43–54. DOI:<a href=&quot;https://doi.org/10.1111/ijlh.14281&quot;>10.1111/ijlh.14281</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38622956/&quot;>https://pubmed.ncbi.nlm.nih.gov/38622956</a></p></li><li><p>Howard, JF, et al., &amp; Wiendl, H (2021). Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis. <i>Expert opinion on investigational drugs</i> 30(5) 483–493. DOI:<a href=&quot;https://doi.org/10.1080/13543784.2021.1897567&quot;>10.1080/13543784.2021.1897567</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33792453/&quot;>https://pubmed.ncbi.nlm.nih.gov/33792453</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AJ06;
